All News ImpediMed Limited

Equities

Market Closed - Australian S.E. Other stock markets 11:40:05 29/04/2024 am IST			5-day change	1st Jan Change
0.089 ^AUD	+3.49%		-1.11%	-38.62%

17/04	Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant	MT
17/04	Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16	MT

Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant	17/04	MT
Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16	17/04	MT
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting	11/04	CI
ImpediMed Limited(ASX:IPD) added to S&P/ASX All Ordinaries Index	18/03	CI
Impedimed Names Independent Non-Executive Chair	27/02	MT
ImpediMed Narrows Loss in Fiscal H1, Revenue Declines; Shares Fall 7%	27/02	MT
Transcript : ImpediMed Limited, H1 2024 Earnings Call, Feb 27, 2024	27/02
ImpediMed Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
ImpediMed Says New Guidelines for Lymphedema Detection Will Help Company Sales	14/02	MT
Transcript : ImpediMed Limited, Q2 2024 Earnings Call, Feb 01, 2024	01/02
Transcript : ImpediMed Limited - Shareholder/Analyst Call	30/11
ImpediMed CEO, CFO Step Down; Shares Fall 11%	20/11	MT
ImpediMed Limited Announces CEO Changes	20/11	CI
ImpediMed Limited Announces CFO Changes	20/11	CI
ImpediMed Limited Announces Management Changes	20/11	CI
ImpediMed Secures Payor Clearance for Spectroscopy Device in the US; Shares Rise 4%	03/11	MT
Morgans rates IPD as Add	01/11	AQ
Transcript : ImpediMed Limited, Q1 2024 Earnings Call, Oct 31, 2023	31/23/31
ImpediMed Limited Announces Resignation of Mrs. Janet West AM as Non-Executive Director	03/23/03	CI
Impedimed Limited Announces Board Changes	28/23/28	CI

No results for this search